Methods of Administering 3,4-Diaminopyridine
AssigneeSerb SA
InventorsMarvin R. GAROVOY, Peter E. HAROLDSEN, Donald G. MUSSON
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.
Claims17
A method of treating a human patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS) in need of treatment thereof comprising administering a total daily dose of 3,4-diaminopyridine (3,4-DAP), or an equivalent amount of a pharmaceutically acceptable salt thereof, to the patient,
- wherein the patient has at least one N-acetyl transferase 2 (NAT2) fast allele, and the total daily dose is about 30 mg to about 240 mg of 3,4-DAP, or an equivalent amount of a pharmaceutically acceptable salt thereof, optionally provided as a series of divided doses, or
- wherein the patient has two NAT2 slow alleles, each NAT2 slow allele is a NAT2*5, *6, *7, or *14 allele, and the total daily dose is about 7.5 mg to about 40 mg of 3,4-DAP, or an equivalent amount of a pharmaceutically acceptable salt thereof, optionally provided as a series of divided doses.
Dependencies are inferred from the claim text.